

Article

Incidence of Cholangitis and Sepsis Associated with Percutaneous Transhepatic Cholangiography in Pediatric Liver Transplant Recipients

Naire Sansotta ^{1,*}, Ester De Luca ², Emanuele Nicastro ¹, Alessandra Tebaldi ³, Alberto Ferrari ⁴ and Lorenzo D'Antiga ¹

¹. Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo postal code, Italy; enicastro@asst-pg23.it (E.N.); ldantiga@asst-pg23.it (L.D.A.)

². Department of Pediatrics, University of Milano Bicocca, Milan postal code, Italy; e.deluca@campus.unimib.it

³. Infectious Diseases Unit, Hospital Papa Giovanni XXIII Bergamo postal code, Italy; atebaldi@asst-pg23.it

⁴. FROM Research Foundation, Statistics, Hospital Papa Giovanni XXIII, Bergamo postal code, Italy; afer-rari34@yahoo.com

* Correspondence: nsansotta@asst-pg23.it

Table S1. Antibiotic susceptibility pattern of germs isolated in blood and bile cultures.

Antibiotic	Germs Isolated									
	<i>Enterococcus faecium</i> N 15	<i>Pseudomonas aeruginosa</i> N 10	<i>Escherichia coli</i> N 5	<i>Klebsiella pneumoniae</i> N 4	<i>Staphylococcus aureus</i> N 2	<i>Enterobacter aerogenes</i> N 2	<i>Enterococcus faecalis</i> N 2	<i>Enterobacter cloacae</i> N 1	<i>Acinetobacter baumannii</i> N 1	
<i>Ampicillin</i>	1/15 (7%)	0/10 (0%)	0/4 (0%)	0/4 (0%)	0/2 (0%)	0/2 (0%)	2/2 (100%)	0/1 (0%)	0/1 (0%)	
<i>Ampicillin-sulbactam</i>	–	0/10 (0%)	1/5 (20%)	0/4 (0%)	2/2 (100%)	0/2 (0%)	–	0/1 (0%)	0/1 (0%)	
<i>Penicillin G</i>	0/15 (0%)	–	–	–	0/2 (0%)	–	0/2 (0%)	–	–	
<i>Piperacillin-Tazobactam</i>	–	5/10 (50%)	3/5 (60%)	0/4 (0%)	–	0/2 (0%)	–	0/1 (0%)	–	
<i>Oxacillin</i>	–	–	–	–	2/2 (100%)	–	–	–	–	
<i>Cefotaxime</i>	–	0/10 (0%)	0/5 (0%)	0/4 (0%)	–	0/2 (0%)	–	–	–	
<i>Cefuroxime</i>	0/15 (0%)	–	–	–	–	–	–	–	–	
<i>Gentamycin</i>	0/3 (0%)	10/10 (100%)	3/5 (60%)	0/4 (0%)	2/2 (100%)	2/2 (100%)	2/2 (100%)	1/1 (100%)	1/1 (100%)	
<i>Cotrimoxazole</i>	–	0/10 (0%)	2/5 (40%)	0/4 (0%)	2/2 (100%)	2/2 (100%)	–	1/1 (100%)	–	
<i>Ciprofloxacin</i>	–	5/10 (50%)	2/5 (40%)	0/4 (0%)	–	1/2 (50%)	–	1/1 (100%)	0/1 (0%)	
<i>Amikacin</i>	–	–	1/2 (50%)	4/4 (100%)	–	–	–	–	1/1 (100%)	
<i>Imipenem</i>	0/15 (0%)	–	2/2 (100%)	2/4 (50%)	–	–	1/2 (50%)	–	–	
<i>Meropenem</i>	–	–	3/3 (100%)	4/4 (100%)	–	2/2 (100%)	–	–	1/1 (100%)	
<i>Ertapenem</i>	–	0/10 (0%)	2/2 (100%)	2/4 (50%)	–	1/2 (50%)	–	0/1 (0%)	0/1 (0%)	
<i>Cefepime</i>	–	–	0/3 (0%)	0/4 (0%)	–	–	–	–	0/1 (0%)	
<i>Colistin</i>	–	2/2 (100%)	1/1 (100%)	–	–	–	–	–	–	
<i>Ceftazidime</i>	–	10/10 (100%)	–	0/4 (0%)	–	0/2 (0%)	–	0/1 (0%)	–	
<i>Tigecycline</i>	2/3 (33%)	0/10 (0%)	1/1 (100%)	2/4 (50%)	–	–	–	–	–	
<i>Fosfomycin</i>	–	–	1/1 (100%)	2/4 (50%)	–	–	1/2 (50%)	–	0/1 (0%)	
<i>Chloramphenicol</i>	–	0/10 (0%)	–	–	–	–	–	–	0/1 (0%)	
<i>Doripenem</i>	–	–	–	2/4 (50%)	–	–	–	–	–	
<i>Streptomycin</i>	1/4 (25%)	–	–	–	–	–	2/2 (100%)	–	–	
<i>Erythromycin</i>	0/15 (0%)	–	–	–	2/2 (100%)	–	0/2 (0%)	–	–	
<i>Clindamycin</i>	0/15 (0%)	–	–	–	2/2 (100%)	–	0/2 (0%)	–	–	
<i>Vancomycin</i>	12/15 (80%)	–	–	–	2/2 (100%)	–	2/2 (100%)	–	–	
<i>Linezolid</i>	4/4 (100%)	–	–	–	–	–	1/2 (50%)	–	–	
<i>Levofloxacin</i>	–	–	–	–	2/2 (100%)	–	–	–	–	
<i>Teicoplanin</i>	1/2 (50%)	–	–	–	–	–	–	–	–	
VRE	3/15	–	–	–	–	–	–	–	–	
ESBL	–	–	2/15	2/4	–	2/2	–	1/1	–	

Car- bapenemase Producing	–	–	1/15	–	–	–	–	–	–
------------------------------------------	---	---	-------------	---	---	---	---	---	---

–: not tested, VRE: vancomycin-resistant Enterococcus sp.; ESBL: extended-spectrum beta-lactamase.